P&G Acquires Thorne Supplement Brand in a $3.8B Health and Wellness Strategy
Consumer goods giant, Procter & Gamble, has announced its largest health and wellness initiative in recent years. On August 4, 2026, it revealed plans to acquire the premium supplement manufacturer, Thorne. The all-cash deal is valued at a staggering $3.8 billion, nearly six times the amount paid by private equity firm L Catterton to privatize the company just three years prior.
The announcement was made by P&G CEO, Shailesh Jejurikar, during a live broadcast on CNBC’s Squawk on the Street. Jejurikar stated that the acquisition is a strategic move to expand the company’s thriving health division.
Established in 1984, Thorne offers a broad range of science-backed supplements. These range from creatine and prenatal vitamins to personalized health products. In 2026, the company was projected to achieve $650 million in annual sales. A significant portion of the brand’s revenue is generated by consumers under the age of 40. Over recent years, its direct-to-consumer channel has seen substantial growth.
P&G will purchase Thorne from L Catterton’s Flagship Fund. This LVMH-backed private equity firm acquired the company for $680 million in 2023. The transaction is set to finalize in Q4 2026, pending regulatory approvals. Following the announcement, P&G shares rose 1.5% to $147.20.
The acquisition of Thorne will supplement P&G’s existing portfolio, which includes brands such as Metamucil, Align Probiotic, New Chapter vitamins, Oral-B, and Vicks. This move is concurrent with Unilever’s recent acquisition of U.S. gummy supplement manufacturer, Grüns. These acquisitions indicate a competitive industry-wide scramble to tap into the burgeoning wellness economy.
Source: CNBC – Procter & Gamble to Acquire Thorne for $3.8 Billion